Asset Details
Do you wish to reserve the book?
Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
Do you wish to request the book?
Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
2023
Overview
Baseline characteristics (N = 14) Age at HCL diagnosis, median (range) 47 (23–67) Sex, n (%) Female 4 (28.6) Male 10 (71.4) COVID-19 diagnosis and vaccination status Vaccinated, n (%) No 3 (21.4) Yes 11 (78.6) First vaccination before positive COVID-19 testing 5 (35.7) First vaccination after positive COVID-19 testing 6 (42.9) Vaccination dose and type, n (%) (n = 11) One dose: The majority of patients in our cohort received COVID-19-directed treatment, which likely improved outcomes. [...]physicians should consider early treatment of COVID-19 with the best available therapies in HCL patients. CONFLICT OF INTEREST STATEMENT James Blachly: AbbVie, AstraZeneca, Astellas, MingSight, patent on a leukemia diagnostic device, patent pending on a leukemia classification scheme.
